 India’s Pharmaceutical Industry in the WTO Regime: A SWOT AnalysisN. Lalitha Working Papers from eSocialSciences Abstract: A SWOT analysis of the Indian Pharmaceutical Industry (IPI) in the WTO regime reveals that the much acclaimed IPI’s expertise in process development skills were made possible by the amendments made to the Indian Patents Act 1970. This strength should be utilized maximum to benefit from opportunities that arise from vertical disintegration of research, clinical trails and manufacturing by the multinationals. The weakness however lies in the fact that such opportunities will be limited to a few firms in this sector. IPI faces threats in the form of competition from other Asian giants particularly China which has similar expertise in process development and reverse engineering. This paper argues that the IPI should adopt various strategies like producing off patented products, new patented products by acquiring compulsory licensing or cross licensing, collaborate with multinationals not only in R&D and manufacturing but also in marketing new patented products and improving the standards of production to widen the export market. GIDR Working Paper 131 , 2002 Keywords: pharmaceutical industry; China; Asia; patented products; compulsory licensing; cross licensing; R and D; exports; multinational firms; SWOT analysis; Indian Patents Act; WTO regime; Economics; Industry; Indian Economy; international trade (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:ess:wpaper:id:453 Access Statistics for this paper More papers in Working Papers from eSocialSciences |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.